Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix r&d expenses
Research and development expenses are spending on new products and technology.
Ocular Therapeutix's R&D Expenses for the twelve months ending Jun 30, 2026 was $223.51M, up 30.0% year over year. For fiscal 2025 it was $197.10M, up 54.4% from the year before. Over ten years it grew 22.2% a year on average. The highest annual figure on record is $197.10M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.10M | +54.4% |
| FY2024 | Dec 31, 2024 | $127.64M | +109.0% |
| FY2023 | Dec 31, 2023 | $61.06M | +14.2% |
| FY2022 | Dec 31, 2022 | $53.46M | +6.7% |
| FY2021 | Dec 31, 2021 | $50.08M | +74.5% |
| FY2020 | Dec 31, 2020 | $28.69M | -30.2% |
| FY2019 | Dec 31, 2019 | $41.09M | +11.3% |
| FY2018 | Dec 31, 2018 | $36.92M | +19.5% |
| FY2017 | Dec 31, 2017 | $30.88M | +14.1% |
| FY2016 | Dec 31, 2016 | $27.07M | +1.7% |
| FY2015 | Dec 31, 2015 | $26.61M | +40.9% |
| FY2014 | Dec 31, 2014 | $18.88M | +79.5% |
| FY2013 | Dec 31, 2013 | $10.52M | -8.9% |
| FY2012 | Dec 31, 2012 | $11.54M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $54.14M | +6.0% |
| Q1 FY2026 | Mar 31, 2026 | $66.21M | +54.5% |
| Q4 FY2025 | Dec 31, 2025 | $50.80M | +23.9% |
| Q3 FY2025 | Sep 30, 2025 | $52.36M | +41.3% |
| Q2 FY2025 | Jun 30, 2025 | $51.08M | +77.0% |
| Q1 FY2025 | Mar 31, 2025 | $42.86M | +106.7% |
| Q4 FY2024 | Dec 31, 2024 | $40.99M | +153.1% |
| Q3 FY2024 | Sep 30, 2024 | $37.05M | +146.7% |
| Q2 FY2024 | Jun 30, 2024 | $28.86M | +91.2% |
| Q1 FY2024 | Mar 31, 2024 | $20.74M | +40.6% |
| Q4 FY2023 | Dec 31, 2023 | $16.20M | +19.6% |
| Q3 FY2023 | Sep 30, 2023 | $15.02M | +9.5% |
| Q2 FY2023 | Jun 30, 2023 | $15.09M | +15.2% |
| Q1 FY2023 | Mar 31, 2023 | $14.75M | +12.6% |
| Q4 FY2022 | Dec 31, 2022 | $13.54M | +7.7% |
| Q3 FY2022 | Sep 30, 2022 | $13.72M | +7.9% |
| Q2 FY2022 | Jun 30, 2022 | $13.10M | -5.5% |
| Q1 FY2022 | Mar 31, 2022 | $13.10M | +19.9% |
| Q4 FY2021 | Dec 31, 2021 | $12.58M | +65.0% |
| Q3 FY2021 | Sep 30, 2021 | $12.72M | +83.0% |
| Q2 FY2021 | Jun 30, 2021 | $13.86M | +72.8% |
| Q1 FY2021 | Mar 31, 2021 | $10.93M | +79.2% |
| Q4 FY2020 | Dec 31, 2020 | $7.62M | -24.7% |
| Q3 FY2020 | Sep 30, 2020 | $6.95M | -32.1% |
| Q2 FY2020 | Jun 30, 2020 | $8.02M | -14.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.10M | -46.1% |
| Q4 FY2019 | Dec 31, 2019 | $10.13M | -1.3% |
| Q3 FY2019 | Sep 30, 2019 | $10.24M | +5.7% |
| Q2 FY2019 | Jun 30, 2019 | $9.41M | +7.7% |
| Q1 FY2019 | Mar 31, 2019 | $11.32M | +37.6% |
| Q4 FY2018 | Dec 31, 2018 | $10.26M | +29.7% |
| Q3 FY2018 | Sep 30, 2018 | $9.69M | +19.2% |
| Q2 FY2018 | Jun 30, 2018 | $8.75M | +7.7% |
| Q1 FY2018 | Mar 31, 2018 | $8.23M | +22.3% |
| Q4 FY2017 | Dec 31, 2017 | $7.91M | +7.9% |
| Q3 FY2017 | Sep 30, 2017 | $8.13M | +42.9% |
| Q2 FY2017 | Jun 30, 2017 | $8.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.33M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.69M | – |
See a number that looks wrong?